Morgan Bayer

In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.

In this weekly recap ODAC endorses MRD for accelerated myeloma trial approval, research delves into ovarian cancer trends in Asian American populations, amivantamab’s variable efficacy in NSCLC, and more.

The FDA approves T-DXd for HER2+ tumors; SynKIR-310 trials begin, and experts debate FLOT vs. CROSS in GEJ cancer in this week’s recap article.

Emerging NK-cell therapies offer faster, safer alternatives to CAR T-cell therapy, improving accessibility and reducing manufacturing challenges. T-DXd shows promise in treating HER2+ tumors, and HPV vaccine offerings during abortion care visits improve vaccination rates.

Recommendations for non–small cell lung cancer biomarker testing in early-stage disease were discussed in a presentation regarding metastatic lung cancer by Christine M. Lovly, MD, PhD.

This week's Targeted Pulse focuses on the latest in cervical cancer, the FDA ODAC's vote for cilta-cel, and more.

This week's Targeted Pulse focuses on the latest in the treatment landscapes of small cell lung cancer, myeloma, and more.

From bispecific antibodies transforming B-cell lymphoma treatment to immunotherapy breakthroughs in breast cancer and gene therapy innovations for hematologic malignancies, recent advancements offer hope.

Orca-T therapy boosts survival in elderly with hematologic cancer, while trilaciclib shows promise in triple-negative breast cancer treatment.

New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.

Allina Health Cancer Institute and Astrin Biosciences are jointly integrating AI to improve the assessment of cancer cells in blood samples, beginning with breast cancer, which faces challenges with mammogram imaging and demands innovative solutions.

A bounty of FDA drug approvals have arrived plus the pivotal role of cytoreductive therapy and more.

In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.

The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.

This week's Targeted Pulse touches on the latest in cancer news and research updates.

This edition of Targeted Pulse dives into the exciting realm of cutting-edge cancer therapies on the horizon.

Real-world, retrospective data showed that morphologic renal cell carcinoma types and tumor-stages helps to inform recurrence and prognosis.

Fostroxacitabine bralpamide combined with lenvatinib showed acceptable safety and tolerability, while inducing promising efficacy in patients with hepatocellular carcinoma.

At 12 months, patients in the experimental arm showed OS rates of 14.4% compared with 11.1% for patients receiving chemotherapy alone in the phase 3, open-label CheckMate649 study.

Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.

The ECHELON-2 study compared brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone chemotherapy with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone regimen for CD30- positive T-cell lymphoma.

Sarah B. Goldberg, MD, MPH, presented these findings to demonstrate the effective time to use immuno-oncology combination therapy during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.

Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.

An ongoing phase 1a/1b trial is set to evaluate NX-1607-101, an oral small-molecule inhibitor of casitas B-lineage lymphoma B designed to enhance innate and adaptive immune responses and demonstrate antitumor activity and long-term survival in patients with persistent lymphoma including those with diffuse large B-cell lymphoma.

New guidelines for gastroenteropancreatic neuroendocrine tumors were issued by the American Society of Clinical Oncology and geared toward community oncologists who often encounter these rare and complex cases infrequently.

Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.